FDA approves Dupixent to treat moderate-to-severe eczema – Clinical Advisor

Posted: April 5, 2017 at 4:22 pm


Clinical Advisor
FDA approves Dupixent to treat moderate-to-severe eczema
Clinical Advisor
(HealthDay News) Dupixent (dupilumab) has been approved by the US Food and Drug Administration to treat moderate-to-severe eczema that isn't well controlled by topical medication. The active ingredient in Dupixent is an antibody (dupilumab) that ...
Dupixent: Eczema's Most Powerful Cure, Approved By FDA ...Science Times
FDA approves Sanofi and Regeneron's new eczema drugEuropean Pharmaceutical Review
FDA Approves $37,000/Yr Eczema Drug | Healthcare PackagingHealthcare Packaging

all 6 news articles »

Read more here:
FDA approves Dupixent to treat moderate-to-severe eczema - Clinical Advisor

Related Posts